Clinical Annotation for rs3786547 (CYP2B6); nevirapine; HIV Infections (level 3 Toxicity)
Level of Evidence
Phenotype Category
Toxicity
Genes
Variant
Drugs
Phenotypes
PharmGKB ID
1444673039
| Allele | Phenotype |
|---|---|
| CC | Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions. |
| CT | Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions. |
| TT | Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions. |
Level of Evidence Calculation More information
- Total Score
- 2.5
- Score Breakdown
- Variant Annotations = 2.5
- Dosing Guideline Annotations = 0
- Drug Label Annotations = 0
- Level Modifiers
- Calculated Level from Score
- Level 3Learn more about Clinical Annotation Levels of Evidence(opens in new window)
Evidence
- 0 Dosing Guideline Annotations
- 0 Drug Label Annotations
- 1 Variant Annotation from 1 Publication
- 1 Positive association Variant Annotation
- 0 Negative association Variant Annotations
1. Annotation of rs3786547 in CYP2B6
Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.
The frequency of the C allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. This SNP was in LD with rs2054674 (r2 = 0.982) and rs3745274 (r2 > 0.90). p-value corrected for multiple testing. This SNP was not associated with hepatic adverse events after correcting for multiple comparisons.
From Publication
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS (London, England). 2011. Yuan Jing et al.
Gene
Variant
Phenotype Category
Association Significance
PharmGKB ID
Score More info on scoring
Study Parameters
Study type
Study size
Association p-value
Statistical analysis
Confidence interval
Biogeographical group More info on groups
Population description
Disease: Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.
History
Loading...